

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

OPTICARE HEALTH SYSTEMS INC
Form 10-Q
May 14, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2004

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

COMMISSION FILE NUMBER 001-15223

OPTICARE HEALTH SYSTEMS, INC.
(Exact Name of Registrant as Specified in Its Charter)

DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)

76-0453392
(I.R.S. Employer
Identification No.)

87 GRANDVIEW AVENUE, WATERBURY, CONNECTICUT
(Address of Principal Executive Offices)

06708
(Zip Code)

Registrant's Telephone Number, Including Area Code:
(203) 596-2236

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).

Yes No

The number of shares outstanding of the registrant's Common Stock, par
value \$.001 per share, at May 3, 2004 was 30,643,561 shares.

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

INDEX TO FORM 10-Q

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets at March 31, 2004,
December 31, 2003 and March 31 2003 (unaudited)

Condensed Consolidated Statements of Operations for the three
months ended March 31, 2004 and 2003 (unaudited)

Condensed Consolidated Statements of Cash Flows for the three
months ended March 31, 2004 and 2003 (unaudited)

Notes to Condensed Consolidated Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item 4. Controls and Procedures

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Item 6. Exhibits and Reports on Form 8-K

SIGNATURE

PART I FINANCIAL INFORMATION

ITEM 1: FINANCIAL STATEMENTS

OPTICARE HEALTH SYSTEMS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (AMOUNTS IN THOUSANDS)
 (UNAUDITED)

	MARCH 31, 2004	DECEMBER 2003
	-----	-----
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$1,925	\$ 1,69
Accounts receivable, net	10,795	9,36
Inventories	6,292	5,91
Deferred income taxes, current	-	
Other current assets	1,110	56
	-----	-----
TOTAL CURRENT ASSETS	20,122	17,54
Property and equipment, net	4,312	4,68
Goodwill, net	19,195	19,19
Intangible assets, net	1,151	1,17
Deferred income taxes, non-current	-	
Other assets	3,251	3,24
	-----	-----
TOTAL ASSETS	\$48,031	\$ 45,85
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$9,620	\$ 5,64
Accrued expenses	5,720	5,50
Current portion of long-term debt	380	1,12
Other current liabilities	1,391	1,55
	-----	-----
TOTAL CURRENT LIABILITIES	17,111	13,82
	-----	-----

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

Long-term debt--related party	-	
Other long-term debt, less current portion	10,174	11,46
Other liabilities	519	51
	-----	-----
TOTAL NON-CURRENT LIABILITIES	10,693	11,98
	-----	-----
Series B 12.5% mandatorily redeemable, convertible preferred stock--related party	5,809	5,63
STOCKHOLDERS' EQUITY:		
Series C preferred stock--related party	1	
Common stock	31	3
Additional paid-in-capital	79,701	79,70
Accumulated deficit	(65,315)	(65,319)
	-----	-----
TOTAL STOCKHOLDERS' EQUITY	14,418	14,41
	-----	-----
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 48,031	\$ 45,85
	=====	=====

See notes to condensed consolidated financial statements.

3

OPTICARE HEALTH SYSTEMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA) (UNAUDITED)

	THREE MONTHS ENDED MARCH 31,	
	2004	2003
	-----	-----
NET REVENUES:		
Managed vision	\$ 6,043	\$ 7,408
Product sales	18,128	17,722
Other services	5,581	5,028
Other income	620	1,838
	-----	-----
Total net revenues	30,372	31,996
	-----	-----
OPERATING EXPENSES:		
Medical claims expense	4,644	5,744
Cost of product sales	13,365	13,901
Cost of services	2,279	2,126
Selling, general and administrative	9,322	8,808

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

Depreciation	403	355
Amortization	28	44
Interest	321	751
	-----	-----
Total operating expenses	30,362	31,729
	-----	-----
Income before income taxes	10	267
Income tax expense	6	107
	-----	-----
Net income	4	160
Preferred stock dividends	(174)	(140)
	-----	-----
Net income (loss) available to common stockholders	\$ (170)	\$ 20
	=====	=====
EARNINGS (LOSS) PER SHARE:		
Net income (loss) per common share:		
Basic	\$ (0.01)	\$ 0.00
Diluted	\$ (0.01)	\$ 0.00

See notes to condensed consolidated financial statements.

4

OPTICARE HEALTH SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN THOUSANDS)
(UNAUDITED)

	FOR THE THREE MO MARCH 3
	----- 2004 -----
OPERATING ACTIVITIES:	
Net income	\$ 4
Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation	403
Amortization	28
Non-cash interest expense	38
Changes in operating assets and liabilities:	
Accounts receivable	(1,426)
Inventory	(374)
Other assets	(602)
Accounts payable and accrued expenses	4,364
Other liabilities	(154)

Net cash provided by operating activities	2,281

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

INVESTING ACTIVITIES:

Cash received on notes receivable	46
Purchase of fixed assets	(32)
Purchase of assets from acquisition, excluding cash	-
Purchase of restricted certificates of deposit	-

Net cash provided by (used in) provided by investing activities 14

FINANCING ACTIVITIES:

Net increase (decrease) in revolving credit facility	(1,920)
Principal payments on long-term debt	(119)
Principal payments on capital lease obligations	(1)
Payment of financing costs	(25)
Proceeds from issuance of common stock	-

Net cash (used in) provided by financing activities (2,065)

Increase in cash and cash equivalents 230
 Cash and cash equivalents at beginning of period 1,695

Cash and cash equivalents at end of period \$ 1,925

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash paid for interest	\$ 286
Cash paid for income taxes	\$ 38

See notes to condensed consolidated financial statements.

OPTICARE HEALTH SYSTEMS, INC. AND SUBSIDIARIES
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)
 (Amounts in thousands, except share data)

1. BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements of OptiCare Health Systems, Inc., a Delaware corporation, and its subsidiaries (collectively the "Company") for the three months ended March 31, 2004 and 2003 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934, as amended, and are unaudited. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

accruals) necessary for a fair presentation of the consolidated financial statements have been included. The results of operations for the three months ended March 31, 2004 are not necessarily indicative of the results to be expected for the full year. The condensed consolidated balance sheet as of December 31, 2003 was derived from the Company's audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

2. STOCK BASED COMPENSATION

The Company accounts for its stock-based compensation plans under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations in accounting for the stock options granted to its employees and directors. Accordingly, employee and director compensation expense is recognized only for those options whose price is less than fair market value at the measurement date.

Statement of Financial Standards ("SFAS") No. 123 "Accounting for Stock-Based Compensation, as amended by SFAS No. 148 "Accounting for Stock-Based Compensation--Transition and Disclosure--an amendment of Statement of Financial Accounting Standard No. 123" requires that companies which do not elect to account for stock-based compensation as prescribed by this statement, disclose the pro forma effects on earnings and earnings per share as if SFAS No. 123 had been adopted. If the Company applied the recognition provisions of SFAS No. 123, the Company's reported net income (loss) and earnings (loss) per share available to common stockholders, using the Black Scholes option pricing model, would have been adjusted to the pro forma amounts indicated below.

	THREE MONTHS ENDED MARCH 31,	
	2004	2003
Net income, as reported	\$ 4	\$ 160
Less: Total stock-based employee compensation expense, net of related tax effects	(23)	(108)
Pro forma net income (loss)	\$ (19)	\$ 52
Basic and diluted earnings (loss) per share:		
As reported	\$ (0.01)	\$ 0.00
Pro forma	\$ (0.01)	\$ 0.00

3. ACQUISITION OF WISE OPTICAL VISION GROUP, INC.

On February 7, 2003, the Company acquired substantially all of the assets and certain liabilities of the contact lens distribution business of Wise Optical Vision Group, Inc. ("Wise Optical"), a New York corporation. The results of operations of Wise Optical are included in the consolidated financial statements from February 1, 2003, the deemed effective date of the acquisition for accounting purposes.

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

Assuming the acquisition of Wise Optical had occurred on January 1, 2003, pro forma net revenue and net income of the Company for the three months ended March 31, 2003 would have been \$38,615 and \$248, respectively. On the same pro forma basis, basic and diluted income per common share for the three months ended March 31, 2003 would have been \$0.00. This unaudited pro forma information is for informational purposes only and is not necessarily indicative of the results that would have been obtained had these events actually occurred at the beginning of the periods presented, nor does it intend to be a projection of future results.

4. INTANGIBLE ASSETS

Intangible assets subject to amortization are comprised of a service agreement and non-compete agreements. The service agreement has a gross carrying amount of \$1,658 and accumulated amortization of \$507, \$479 and \$396 at March 31, 2004, December 31, 2003 and March 31, 2003, respectively. The non-compete agreements, which had a gross carrying amount of \$265, were fully amortized at March 31, 2004 and December 31, 2003 and had accumulated amortization of \$218 at March 31, 2003. Amortization expense for the three months ended March 31, 2004 and 2003 was \$28 and \$44, respectively. Estimated annual amortization expense is expected to be \$111 in each of the years 2004 through 2008.

5. SEGMENT INFORMATION

The Company is an integrated eye care services company focused on providing managed vision and professional eye care products and services. The Company has the following three reportable operating segments: (1) Managed Vision, (2) Consumer Vision, and (3) Distribution and Technology. These operating segments are managed separately, offer separate and distinct products and services, and serve different customers and markets, although there is some cross-marketing and selling between the segments. Discrete financial information is available for each of these segments and the Company's President assesses performance and allocates resources among these three operating segments.

The Managed Vision segment contracts with insurers, insurance fronting companies, employer groups, managed care plans and other third party payors to manage claims payment administration of eye health benefits for those contracting parties. The Consumer Vision segment sells retail optical products to consumers and operates integrated eye health centers and surgical facilities in Connecticut where comprehensive eye care services are provided to patients. The Distribution and Technology segment provides products and services to eye care professionals (ophthalmologists, optometrists and opticians) through (i) Wise Optical, a distributor of contact and ophthalmic lenses and other eye care accessories and supplies; (ii) a Buying Group program, which provides group purchasing arrangements for optical and ophthalmic goods and supplies and (iii) CC Systems, which provides systems and software solutions to eye care professionals.

In addition to its reportable operating segments, the Company's "All Other" category includes other non-core operations and transactions, which do not meet the quantitative thresholds for a reportable segment. Included in the "All Other" category is revenue earned under the Company's health service organization ("HSO") operation, which receives fee income for providing certain support services to individual ophthalmology and optometry practices. The Company is in the process of disengaging from its HSO arrangements.

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

7

Management assesses the performance of its segments based on income before income taxes, interest expense, depreciation and amortization, and other corporate overhead. Summarized financial information, by segment, for the three months ended March 31, 2004 and 2003 is as follows:

	THREE MONTHS ENDED MARCH 31,	
	2004	2003
REVENUES:		
Managed vision	\$6,051	\$7,408
Consumer vision	8,143	7,306
Distribution and technology	17,191	16,420
Reportable segment totals	31,385	31,134
All other	633	1,861
Elimination of inter-segment revenues	(1,646)	(999)
Total net revenue	\$ 30,372	\$ 31,996
SEGMENT INCOME (LOSS):		
Managed vision	\$ 166	\$426
Consumer vision	931	565
Distribution and technology	53	(270)
Reportable segment totals	1,150	721
All other	424	1,677
Depreciation	(403)	(355)
Amortization	(28)	(44)
Interest expense	(321)	(751)
Corporate	(812)	(981)
Income before income taxes	\$ 10	\$ 267

6. EARNINGS (LOSS) PER COMMON SHARE

The following table sets forth the computation of basic and diluted earnings (loss) per share:

	THREE MONTHS ENDED MARCH 31,	
	2004	2003

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

BASIC EARNINGS (LOSS) PER SHARE:

Net income	\$ 4	\$ 16
Preferred stock dividend	(174)	(140)
	-----	-----
Net income (loss) available to common Stockholders	\$ (170)	\$ 2
	=====	=====
Average common shares outstanding (basic)	30,388,891	29,543,09
Basic earnings (loss) per share:	\$ (0.01)	\$ 0.0
	=====	=====

8

THREE MONTHS ENDED MARCH 31,

	2004	2003
	-----	-----
DILUTED EARNINGS (LOSS) PER SHARE:		
Income (loss) available to common stockholders	\$ (170)	\$ 2
Assumed conversions of preferred stock dividends	*	14
	-----	-----
Net income (loss) available to common stockholders	\$ (170)	\$ 16
	=====	=====
Average common shares outstanding (basic)	30,388,891	29,543,09
Effect of dilutive securities:		
Options	*	4,152,50
Warrants	*	1,045,00
Convertible Preferred stock	*	36,845,91
	-----	-----
Diluted shares	30,388,891	71,586,50
	=====	=====
Diluted earnings (loss) per share:	\$ (0.01)	\$ 0.0
	=====	=====

* Anti-dilutive

The following table reflects the potential common shares of the Company for the three months ended March 31, 2004 and 2003 that have been excluded from the calculation of diluted earnings per share due to anti-dilution.

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

	THREE MONTHS ENDED	
	MARCH 31,	
	2004	2003
Options	6,160,289	2,054,566
Warrants	3,125,000	2,080,000
Convertible Preferred Stock	61,801,304	-
	-----	-----
	71,086,593	4,134,566
	=====	=====

7. CONTINGENCIES

The Company is both a plaintiff and defendant in lawsuits incidental to its current and former operations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Consequently, the ultimate aggregate amount of monetary liability or financial impact with respect to these matters at March 31, 2004 cannot be ascertained. Management is of the opinion that, after taking into account the merits of defenses and established reserves, the ultimate resolution of these matters will not have a material adverse impact on the Company's consolidated financial position or results of operations.

9

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion may be understood more fully by reference to our consolidated financial statements, notes to the consolidated financial statements, and management's discussion and analysis contained in our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission.

OVERVIEW

We are an integrated eye care services company focused on vision benefits management (managed vision), retail optical sales and eye care services to patients and the distribution of products and software services to eye care professionals.

Our business is comprised of three reportable operating segments: (1) Managed Vision, (2) Consumer Vision, and (3) Distribution & Technology. Our Managed Vision segment contracts with insurers, managed care plans and other third party payers to manage claims payment administration of eye health benefits for those contracting parties. Our Consumer Vision segment sells retail optical products to consumers and operates integrated eye health centers and surgical facilities in Connecticut where comprehensive eye care services are provided to patients. The Distribution and Technology segment provides products and services to eye care professionals (ophthalmologists, optometrists and opticians) through (i) Wise Optical, a distributor of contact and ophthalmic lenses and other eye care accessories and supplies; (ii) a Buying Group program, which provides group purchasing arrangements for optical and ophthalmic goods and supplies and (iii) CC Systems, which provides systems and software solutions

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

to eye care professionals.

In addition to these segments, we receive income from other non-core operations and transactions, including our health service organization (HSO) operation, which receives fee income for providing certain support services to individual ophthalmology and optometry practices. We are in the process of disengaging from our HSO arrangements.

We experienced losses at Wise Optical throughout 2003. In September 2003, we began implementing strategies and operational changes to turn around Wise Optical. These strategies included growing sales through improved customer service, improving gross margin through pricing discipline and active purchasing strategies as well as reducing operating expenses through the elimination of positions and tightening of expense policies. In the first quarter of 2004, as a result of these strategies, Wise Optical achieved sales growth, increased gross margins and reduced operating expenses. We expect continued improvement in the operating results of Wise Optical in the future as we continue executing these strategies.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

Managed Vision revenue. Managed Vision revenue represents fees received under our managed care contracts. Managed Vision revenue decreased to approximately \$6.0 million for the three months ended March 31, 2004 compared to approximately \$7.4 million for the three months ended March 31, 2003, a decrease of approximately \$1.4 million or 18.9%. Of this decrease, approximately \$1.3 million is due to terminated contracts, primarily as a result of changes made by the Texas state legislature to its Medicaid and Children's Health Insurance Programs, and \$0.6 million is due to a decline in membership in existing contracts with the insurer CIGNA. These decreases are partially offset by increases in revenue of approximately \$0.3 million from new contracts and approximately \$0.2 million from net growth in existing contracts. We expect the decrease in revenue associated with the CIGNA contracts to be more than offset by revenue under a new contract with a different payor, which became effective March 1, 2004. We expect managed vision revenue to increase in the future as we enter into new direct-to-employer contracts.

Product sales revenue. Product sales include the retail sale of optical products in our Consumer Vision segment, the sale of optical products through our Buying Group and the sale of contact and ophthalmic lenses through Wise Optical. Product sales revenue increased to approximately \$18.1 million for the three months ended March 31, 2004 compared to approximately \$17.7 million for the three months ended March 31, 2003, an increase of approximately \$0.4 million or 2.3%. This increase represents an approximate \$1.0 million increase in revenue from Wise Optical and

an approximate \$0.2 million increase in revenue from Consumer Vision, which were partially offset by an approximate \$0.8 million decrease in revenue from the Buying Group. Revenue of Wise Optical was approximately \$1.0 higher in the first quarter of 2004 as compared to the first quarter of 2003, because 2004 revenue included a full quarter of revenue, whereas 2003 revenue only included revenue from February 1, 2003, the effective date of our acquisition of Wise Optical. The increase in Wise Optical revenue due to the additional month of revenue in 2004 is partially offset by the overall decline in sales volume we experienced

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

immediately after we purchased Wise Optical. We began implementing strategies in September 2003 to increase sales at Wise Optical and we have experienced improved revenue since we began that initiative. We expect future sales at Wise Optical to approximate current levels, adjusted for seasonal fluctuations. The increase in Consumer Vision product sales is primarily due to an increase in purchasing volume associated with improved sales efforts and increased sales of higher value products through incentive programs and product promotions. We expect Consumer Vision product sales to continue to increase throughout the year, adjusted for seasonal fluctuations. The decrease in Buying Group revenue is due to a decrease in purchasing volume primarily due to the loss of the business of Optometric Eye Care Center, P.A., which occurred in the second quarter of 2003. We expect product sales of the Buying Group to remain at current levels for the remainder of the year, adjusted for seasonality.

Other services revenue. Other services revenue includes revenue earned from providing eye care services in our Consumer Vision segment, software services in our Distribution & Technology segment and HSO services. Other services revenue increased to approximately \$5.6 million for the three months ended March 31, 2004 compared to approximately \$5.0 million for the three months ended March 31, 2003, an increase of approximately \$0.6 million or 12.0%. This increase is primarily due to increased services volume in the medical, optometry and surgical areas attributable to increased doctor coverage and productivity. We expect services revenue to remain at these levels or increase slightly in the future, adjusted for seasonality.

Other income. Other income represents non-recurring settlements on HSO contracts. Other income for the three months ended March 31, 2004 was approximately \$0.6 million compared to approximately \$1.8 million for the three months ended March 31, 2003, representing a decrease of approximately \$1.2 million or 66.7%, as a result of a decrease in the number of settlements in the current quarter.

Medical claims expense. Medical claims expense decreased to approximately \$4.6 million for the three months ended March 31, 2004, from approximately \$5.7 million for the three months ended March 31, 2003, a decrease of approximately \$1.1 million or 19.3%. The medical claims expense loss ratio (MLR) representing medical claims expense as a percentage of Managed Vision revenue decreased to 76.8% in 2004 from 77.5% in 2003. The favorable change in MLR is a result of changes to existing contracts and increased revenue from certain contracts which do not generate claims expense. We expect claims expense to increase in the future as we enter into additional direct-to-employer contracts.

Cost of product sales. Cost of product sales decreased to approximately \$13.4 million for the three months ended March 31, 2004 compared to approximately \$13.9 million for the three months ended March 31, 2003, a decrease of approximately \$0.5 million or 3.6%. This decrease is primarily due to an approximate \$0.8 million decrease in product costs associated with the decrease in Buying Group sales, which was partially offset by an approximate \$0.2 million increase in product costs associated with increased sales in our Consumer Vision division and \$0.1 million increase in Wise Optical product costs. The increase in Wise Optical product costs is because 2004 product costs included a full quarter of Wise Optical costs, whereas 2003 product costs only included costs from February 1, 2003, the effective date of our acquisition of Wise Optical. This increase in Wise Optical product costs in 2004 is partially offset by a decrease in its product costs as a result of a decrease in sales volume. Overall, we expect total product costs to increase slightly in the future due to an expected increase in product sales.

Cost of services. Cost of services increased to approximately \$2.3 million for the three months ended March 31, 2004 compared to approximately \$2.1 million for the three months ended March 31, 2003, an increase of approximately \$0.2 million or 9.5%. This increase is primarily due to the increased services volume

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

in the Consumer Vision area.

Selling, general and administrative expenses. Selling, general and administrative expenses increased to approximately \$9.3 million for the three months ended March 31, 2004 compared to approximately \$8.8 million for the three months ended March 31, 2003, an increase of approximately \$0.5 million or 5.7%. The increase in 2004 is primarily due to expenses associated with Wise Optical's operations being included in our results for a full quarter, whereas 2003 expenses only included Wise Optical from February 1, 2003, the effective date of our acquisition of Wise Optical.

11

Interest expense. Interest expense decreased to approximately \$0.3 million for the three months ended March 31, 2004 from approximately \$0.8 million for the three months ended March 31, 2003, a decrease of approximately \$0.5 million or 62.5%. This decrease in interest expense is primarily due to a decrease in the average outstanding debt balance as a result of the conversion of approximately \$16.2 million of debt to preferred stock in May 2003.

Income tax expense. Income tax expense for the three months ended March 31, 2004 primarily represents minimum state tax expense. Income tax expense of approximately \$0.1 million for the three months ended March 31, 2003, represents tax expense on income from operations of approximately \$0.3 million, at an effective rate of 40%.

CRITICAL ACCOUNTING ESTIMATES

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities at the date of our financial statements. Management bases its estimates and judgments on historical experience, current economic and industry conditions and on various other facts that are believed to be reasonable under the circumstances. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

Management believes critical accounting estimates are used in determining the adequacy of the allowance for doubtful accounts, insurance disallowances, managed care claims accrual, valuation allowance for deferred tax assets and in evaluating goodwill and intangibles for impairment.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

Our primary sources of liquidity have been cash flows generated from operations in our Managed Vision and Consumer Vision segments and borrowings under our term loan and revolving credit facility.

As of March 31, 2004, we had cash and cash equivalents of approximately \$1.9 million and approximately \$2.5 million of additional availability under our revolving credit facility with CapitalSource.

The following table sets forth a quarter-over-quarter comparison of the components of our liquidity and capital resources for the quarters ended March 31, 2004 and 2003:

(In millions)

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

	2004	2003	\$ CHANGE
	----	----	-----
Cash and cash equivalents	\$ 1.9	\$ 3.9	\$ (2.0)
Cash provided by (used in):			
Operating activities	2.3	0.6	1.7
Investing activities	-	(6.4)	6.4
Financing activities	(2.1)	6.6	(8.7)

Net cash provided by operating activities was approximately \$2.3 million for the three months ended March 31, 2004 compared to approximately \$0.6 million for the three months ended March 31, 2003, an increase of approximately \$1.7 million. The increase in cash provided by operating activities was primarily due to improved inventory management and an increase in accounts payable due to higher product sales and the timing of purchases and payments on payables.

There were no significant sources or uses of cash related to investing activities for the three months ended March 31, 2004. Net cash used in investing activities for the three months ended March 31, 2003 was approximately \$6.4 million, which was primarily used to purchase the assets of Wise Optical in February 2003.

12

Net cash used in financing activities was approximately \$2.1 million for the three months ended March 31, 2004 compared to approximately \$6.6 million of net cash provided by financing activities for the three months ended March 31, 2003. Net cash used in financing activities in 2004 was primarily used for repayments under our revolving credit facility. Net cash provided by financing activities in 2003 was primarily from borrowings under our revolving credit facility used to fund the purchase of Wise Optical in February 2003.

We believe that our cash flow from operations, borrowings under our term loan and revolving credit facility with CapitalSource, operating and capital lease financing, and other short-term financing arrangements will provide us with sufficient funds to finance our operations for the next 12 months.

The CapitalSource Loan and Security Agreement

As of March 31, 2004, we had approximately \$2.0 million of borrowings outstanding under our term loan with CapitalSource, approximately \$8.5 million of advances outstanding under our revolving credit facility with CapitalSource and approximately \$2.5 million of additional availability under our revolving credit facility.

The term loan and revolving credit facility with CapitalSource are subject to a Loan and Security Agreement. The Loan and Security Agreement contains certain restrictions on the conduct of our business, including, among other things, restrictions on incurring debt, purchasing or investing in the securities of, or acquiring any other interest in, all or substantially all of the assets of any person or joint venture, declaring or paying any cash dividends or making any other payment or distribution on our capital stock, and creating or suffering liens on our assets. We are required to maintain certain financial covenants, including a minimum fixed charge ratio and to maintain a minimum net worth. Upon the occurrence of certain events or conditions described in the Loan and Security Agreement (subject to grace periods in certain cases), including our failure to meet the financial covenants, the entire outstanding balance of principal and interest would become immediately due and payable. In January and February 2004, we did not meet our fixed charge ratio covenant,

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

primarily due to operating losses incurred at Wise Optical, but received a waiver on our non-compliance from CapitalSource. As of March 31, 2004, we were in compliance with all of our debt covenants.

On March 29, 2004, we entered into the Second Amended and Restated Credit Facility which, among other things, confirmed that our \$0.7 million temporary over-advance in November 2003 was fully repaid on February 29, 2004, changed the expiration date of the waiver of our fixed ratio covenant from March 31, 2004 to February 29, 2004 and reduced the tangible net worth covenant from \$(10) million to \$(2) million. We paid CapitalSource a \$25,000 financing fee in connection with this amendment.

Our term loan and revolving credit facility with CapitalSource mature on January 25, 2006. We are required to make monthly principal payments of \$25,000 on the term loan with the balance due at maturity. Although we may borrow up to \$15 million under the revolving credit facility, the maximum amount that may be advanced is limited to the value derived from applying advance rates to eligible accounts receivable and inventory. The advance rate under our revolving credit facility is 85% of all eligible accounts receivable and 50 to 55% of all eligible inventory. The interest rate applicable to the term loan equals the prime rate plus 3.5% (but not less than 9%) and the interest rate applicable to the revolving credit facility is prime rate plus 1.5% (but not less than 5.75%).

If we terminate the revolving credit facility prior to December 31, 2004, we must pay CapitalSource a termination fee of \$300,000. If we terminate the revolving credit facility after December 31, 2004 but prior to the expiration of the revolving credit facility the termination fee is \$150,000. Additionally, if we terminate the revolving credit facility pursuant to a refinancing with another commercial financial institution, we must pay CapitalSource, in lieu of the termination fee, a yield maintenance amount equal to the difference between (i) the all-in effective yield which could be earned on the revolving balance through January 25, 2006, and (ii) the total interest and fees actually paid to CapitalSource on the revolving credit facility prior to the termination date or date of prepayment.

Our subsidiaries guarantee payments and other obligations under the revolving credit facility and we (including certain subsidiaries) have granted a first-priority security interest in substantially all our assets to CapitalSource. We also pledged the capital stock of certain of our subsidiaries to CapitalSource.

We believe that we will be able to comply with our financial covenants under our amended credit facility with CapitalSource, including our minimum fixed charge ratio covenant, the waiver with respect to which expired on

February 29, 2004. However, if we incur operating losses and we fail to comply with our financial covenants in the future or otherwise default on our debt, our creditors could foreclose on our assets, in which case we would be obligated to seek alternate sources of financing. There can be no assurance that alternate sources of financing will be available to us on terms acceptable to us, if at all. If additional funds are needed, we may attempt to raise such funds through the issuance of equity or convertible debt securities. If additional funds are raised through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders will be reduced and our stockholders may experience dilution of their interest in us. If additional funds are needed and are not available or are not available on acceptable terms, our ability to fund our operations, take advantage of unanticipated opportunities, develop or enhance services or products or otherwise respond to competitive pressures may

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

be significantly limited and may have a material adverse impact on our business and operations.

The Series B Preferred Stock

As of March 31, 2004, we had 3,204,959 shares of Series B Preferred Stock issued and outstanding. Subject to the senior liquidation preference of the Series C Preferred Stock described below, the Series B Preferred Stock ranks senior to all other currently issued and outstanding classes or series of our stock with respect to dividends, redemption rights and rights on liquidation, winding up, corporate reorganization and dissolution. Each share of Series B Preferred Stock is convertible into a number of shares of common stock equal to such share's current liquidation value, divided by a conversion price of \$0.14, subject to adjustment for dilutive issuances. The number of shares of common stock into which each share of Series B Preferred Stock is convertible will increase over time because the liquidation value of the Series B Preferred Stock, which was \$1.81 per share as of March 31, 2004, increases at a rate of 12.5% per year, compounded annually.

The Series C Preferred Stock

As of March 31, 2004, we had 406,158 shares of Series C Preferred Stock issued and outstanding. The Series C Preferred Stock has an aggregate liquidation preference of approximately \$16.2 million and ranks senior to all other currently issued and outstanding classes or series of our stock with respect to liquidation rights. Each share of Series C Preferred Stock is convertible into 50 shares of common stock and has the same dividend rights, on an as converted basis, as our common stock.

Seasonality

Our revenues are generally affected by seasonal fluctuations in the Consumer Vision and Distribution and Technology segments. During the winter and summer months, we generally experience a decrease in patient visits and product sales. As a result, our cash, accounts receivable, and revenues decline during these periods and, because we retain certain fixed costs related to staffing and facilities, our cash flows can be negatively affected.

Impact of Reimbursement Rates

Our revenue is subject to pre-determined Medicare reimbursement rates which, for certain products and services, have decreased over the past three years. A decrease in Medicare reimbursement rates could have an adverse effect on our results of operations if we cannot manage these reductions through increases in revenues or decreases in operating costs. To some degree, prices for health care are driven by Medicare reimbursement rates, so that our non-Medicare business is also affected by changes in Medicare reimbursement rates.

FORWARD-LOOKING INFORMATION AND RISK FACTORS

The statements in this Form 10-Q and elsewhere (such as in other filings by the Company with the Securities and Exchange Commission, press releases, presentations by the company or its management and oral statements) that relate to matters that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document and elsewhere, words such as "anticipate," "believe," "expect," "plan," "intend," "estimate," "project," "will," "could," "may," "predict" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, those relating to:

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

- o Our expectation of future revenue and expense levels;

14

- o Our belief that we will be able to comply with our financial covenants under our amended credit facility with CapitalSource;
- o Our opinion that the outcome of lawsuits will not have a material adverse impact on our consolidated financial position or results of operations;
- o Our expectation of continued improvement in operating results of Wise Optical in the future;
- o Our expected future sales levels;
- o Our expected impact of future interest rates on income and cash flows; and
- o Our belief that cash from operations, borrowings under our term loan and revolving credit facility, and operating and capital lease financings will provide sufficient funds to finance operations for the next 12 months.

In addition, such forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results expressed or implied by such forward-looking statements. Also, our business could be materially adversely affected and the trading price of our common stock could decline if any of the following risks and uncertainties develop into actual events. Such risk factors, uncertainties and the other factors include:

- o Changes in the regulatory environment applicable to our business, including health-care cost containment efforts by Medicare, Medicaid and other third-party payers;
- o Risks related to the eye care industry, including the cost and availability of medical malpractice insurance, and adverse long-term experience with laser and other surgical vision correction;
- o The fact that managed care companies face increasing threats of private-party litigation, including class actions, over the scope of care that the managed care companies must pay for;
- o Loss of the services of key management personnel could adversely effect our business;
- o Our ability to execute our growth strategy, without which we may not become profitable or sustain our profitability;
- o Our ability to obtain additional capital, without which our growth could be limited;
- o The fact that we have a history of losses and may incur further losses in the future;
- o Our ability to maintain the listing of our common stock on the

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

American Stock Exchange;

- o The fact that if we default on our debt to CapitalSource, it could foreclose on our assets;
- o The possibility that we may not compete effectively with other eye care services companies which have more resources and experience than us;
- o Failure to negotiate profitable capitated fee arrangements could have a material adverse effect on our results of operations and financial condition;
- o The possibility that we may have potential conflicts of interests with respect to related party transactions which could result in certain of our officers, directors and key employees having interests that differ from us and our stockholders;
- o Health care regulations or health care reform initiatives, could materially adversely affect our business, financial condition and results of operations;
- o The fact that the company is dependent upon letters of credit or other forms of third party security in connection with certain of its contractual arrangements and, thus, would be adversely affected in the event it was unable to obtain such credit as needed;
- o The fact that we may not realize the expected benefits from our acquisition of Wise Optical;
- o The fact that our largest stockholder, Palisade Concentrated Equity Partnership, L.P., owns sufficient shares of our common stock and voting equivalents to significantly affect the results of any stockholder vote and control our board of directors;
- o The fact that conflicts of interest may arise between Palisade and OptiCare;
- o The fact that we may fail financial covenants in the future; and
- o Other risks and uncertainties discussed elsewhere in this Form 10-Q and detailed from time to time in our periodic earnings releases and reports filed with the Securities and Exchange Commission.

15

Except as required by law, we undertake no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to market risk from exposure to changes in interest rates based on our financing activities under our credit facility with CapitalSource, due to its variable interest rate. The nature and amount of our indebtedness may vary as a result of future business requirements, market conditions and other factors. The extent of our interest rate risk is not quantifiable or predictable

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

due to the variability of future interest rates and financing needs.

We do not expect changes in interest rates to have a material effect on income or cash flows in the year 2004, although there can be no assurances that interest rates will not significantly change. A 10% change in the interest rate payable by us on our variable rate debt would have increased or decreased the three-month interest expense by approximately \$22,000 assuming that our borrowing level is unchanged. We did not use derivative instruments to adjust our interest rate risk profile during the three months ended March 31, 2004.

ITEM 4: CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were adequate and effective to ensure that material information relating to us, including our consolidated subsidiaries, was made known to them by others within those entities, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

HEALTH SERVICE ORGANIZATION LAWSUITS

In January 2004 and March 2004, we reached settlement with Downing-McPeak Vision Centers, P.S.C. and John E. Downing, M.D., and Milne Eye Medical Center, P.C. and Milton J. Milne, M.D., respectively, two HSO practices with which we were in litigation in the matter of In re Prime Vision Health, Inc. Contract Litigation, MDL 1466, which was previously reported in our Annual Report on Form 10-K for the year ended December 31, 2003. These settlements resulted in cash payments to us and mutual termination of the HSO service agreements.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

a. Exhibits

The following Exhibits are filed as part of this Quarterly Report on Form 10-Q:

EXHIBIT	DESCRIPTION
-----	-----
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

b. Reports on Form 8-K

On March 31, 2004 we furnished information regarding results of our quarter and year ended December 31, 2003 under Item 12 (Results of Operation and Financial Condition) on a Current Report on Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned, hereunto duly authorized.

Date: May 14, 2004 OPTICARE HEALTH SYSTEMS, INC.

By: /s/ William A. Blaskiewicz

William A. Blaskiewicz
Vice President and Chief Financial Officer
(Principal Financial and Accounting
Officer and duly authorized officer)

Edgar Filing: OPTICARE HEALTH SYSTEMS INC - Form 10-Q

EXHIBIT	DESCRIPTION
-----	-----
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.